Iliescu EL, et al. - In order to determine the efficacy, tolerability as well as the safety profile of paritaprevir/ombitasvir/ritonavir and dasabuvir among patients suffering renal impairment, researchers performed this real-world evidence study. Participants were patients with chronic kidney disease (n = 232) who were receiving paritaprevir/ombitasvir/ritonavir and dasabuvir for the treatment of chronic hepatitis C infection - genotype 1b. At the commencement of treatment, monthly during therapy and three months following therapy completion, renal and liver function were evaluated in this observational prospective study. In the setting of renal dysfunction, hepatitis C virus (HCV) treatment has always been a challenging subject. Promising effects of direct-acting antivirals, with good tolerance and efficacy in patients with HCV infection and renal impairment, were revealed. In this study population, the sustained virologic response was found to be 100%.